Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prostacalman
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Oral
01
Overview
Prostacalman is an approved homeopathic medicine developed and marketed by PharmaSGP. It is formulated as oral drops (solution) containing a combination of three active homeopathic ingredients: Serenoa repens (saw palmetto), Pareira brava (velvet leaf), and Populus tremuloides (American aspen). Prostacalman is indicated for the treatment of bladder inflammation (cystitis) and urinary complaints (such as frequent urination, weak urine flow, and residual urine) associated with benign prostatic enlargement (benign prostatic hyperplasia).
- Brand names
- Prostacalman
- Other names
- Serenoa repens + Pareira brava + Populus tremuloides
Beyond the preview
Go deeper on Prostacalman.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prostacalman.